Virica Biotech

Ottawa startup announced this week it’s landed $400,000 in federal government funding to help the National Research Council of Canada develop a gene therapy to treat lipoprotein lipase deficiency.
Ottawa firm inks deal to help Oxford Biomedica improve the yield and production efficiency of its next-generation gene therapies.
Company's revenues have more than doubled in the past year, and CEO expects headcount to grow from 16 to at least 30 by next year as demand for its products ramps up.
Local economic development agencies are doing their best to help give the city’s fledgling biotech and medical devices sector a leg up